Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. Lantern's investigational drug candidate, LP-184, has ...
Lantern Pharma has won a trio of rare-pediatric-disease designations from the Food and Drug Administration for its investigational drug candidate LP-184 in multiple ultra-rare children's cancers.
Typically, ultrasonography is the first-line imaging method of evaluating children with liver tumors. But few studies were performed to describe in detail the differentiation between the two types ...
An Upstate mom shares the uphill battle to recovery from her daughter's cancer and is grateful for where they are now. Kylie Jeter, 3, is an energetic little girl, but just a few years ago, it was a ...